EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)

Efficacy, safety, and biomarker analysis of neoadjuvant camrelizumab plus apatinib as a chemotherapy-free strategy for early-stage triple-negative breast cancer: a phase II study

Zhenluan Tian, Hengyu Li, Yuxin Deng, Herui Yao, Ying Wang, Liang Jin, Heran Deng, Na Chen, Jieqiong Liu iD

Breast Cancer Research and Treatment · 2026

DOI: 10.1007/s10549-026-08066-5 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Breast Cancer Research and Treatment, 2026. Verfasst von Zhenluan Tian und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Tumour Centre, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Neoadjuvant Therapy, Pyridines, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 26 Literaturangaben. Gefördert von: Natural Science Foundation of China, National Major Science and Technology Projects of China, CSCO Clinical Oncology Research Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Neoadjuvant chemotherapy, a cornerstone of early-stage triple-negative breast cancer (TNBC) treatment, has limited efficacy and is often accompanied by substantial toxicity. As a promising chemotherapy-free alternative, the combination of immune checkpoint inhibitors and anti-angiogenic agents provides the potential to enhance antitumor efficacy by remodeling the tumor microenvironment while reducing treatment-related adverse events (TRAEs). This study aimed to assess the clinical value and feasibility of neoadjuvant camrelizumab plus apatinib in patients with early-stage TNBC. METHODS: This study enrolled stage II-III TNBC patients with baseline tumor-infiltrating lymphocytes (TILs) > 10%. Participants received 8 cycles of neoadjuvant treatment, consisting of intravenous camrelizumab 200 mg every 21 days (or 3 mg/kg for patients weighing < 50 kg), combined with oral apatinib 250 mg daily. The primary endpoint was pathological complete response (pCR) rate; secondary endpoints included objective response rate (ORR), disease-free survival (DFS), overall survival, and safety. RESULTS: Between December 2022 and March 2024, 25 patients were screened, 14 were recruited and treated, 13 were evaluable for efficacy, and 11 subsequently underwent surgery. The results showed a pCR rate of 27.3% (3/11), an ORR of 46.2% (6/13), and a 24-month DFS rate of 90.9%. TRAEs were predominantly of grade 1-2, with grade ≥ 3 events occurring in 28.6% patients. Exploratory transcriptomic analysis identified differences in genes related to extracellular matrix remodeling and immune regulation. CONCLUSIONS: Camrelizumab plus apatinib demonstrated manageable toxicity and preliminary antitumor activity, supporting further investigation of this chemotherapy-free strategy in early-stage TNBC patients with enriched TILs. TRIAL REGISTRATION: NCT05556200 (Registration Date: September 27, 2022).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Triple Negative Breast NeoplasmsNeoadjuvant TherapyPyridinesAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorAntibodies, Monoclonal, HumanizedHumansFemaleMiddle AgedAdultNeoplasm StagingPathologic Complete ResponseLymphocytes, Tumor-InfiltratingAgedTreatment Outcome

Stichwörter der Autor:innen

Anti-angiogenic therapyImmune checkpoint inhibitorsNeoadjuvant therapyTriple-negative breast cancer

Substanzen

apatinibcamrelizumabPyridinesBiomarkers, TumorAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Breast Tumour Centre, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.
  • Guangdong Provincial Key Laboratory of Malignant Tumour Epigenetics and Gene Regulation, Guangdong-Hong Kong Joint Laboratory for RNA Medicine, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong…
  • Department of Breast and Thyroid Surgery, Changhai Hospital, Navy Medical University (Second Military Medical University), Shanghai, China.
  • Department of Breast Surgery, Shenshan Medical Center, Memorial Hospital of Sun Yat-sen University, Shanwei, Guangdong, China.
  • Department of Breast Tumour Centre, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China. liujieqiong01@163.com.

ORCID-Profile: Jieqiong Liu

Förderung

  • Natural Science Foundation of China
  • National Major Science and Technology Projects of China
  • CSCO Clinical Oncology Research Foundation
  • Sun Yat-Sen Memorial Hospital Clinical Research 5010 Program
  • Sun Yat-Sen Memorial Hospital Medical Scientist Program
  • Guangdong Provincial Key Laboratory of Cancer Pathogenesis and Precision Diagnosis and Treatment
  • DCMST.NHC Clinical Research Project

Zitieren

APA

Tian, Z., Li, H., Deng, Y., Yao, H., Wang, Y., Jin, L., Deng, H., Chen, N., & Liu, J. (2026). Efficacy, safety, and biomarker analysis of neoadjuvant camrelizumab plus apatinib as a chemotherapy-free strategy for early-stage triple-negative breast cancer: a phase II study. Breast Cancer Research and Treatment. https://doi.org/10.1007/s10549-026-08066-5

Vancouver

Tian Z, Li H, Deng Y, Yao H, Wang Y, Jin L, et al. Efficacy, safety, and biomarker analysis of neoadjuvant camrelizumab plus apatinib as a chemotherapy-free strategy for early-stage triple-negative breast cancer: a phase II study. Breast Cancer Research and Treatment. 2026. doi:10.1007/s10549-026-08066-5

BibTeX
@article{Tian2026,
  author = {Tian, Zhenluan and Li, Hengyu and Deng, Yuxin and Yao, Herui and Wang, Ying and Jin, Liang and Deng, Heran and Chen, Na and Liu, Jieqiong},
  title = {Efficacy, safety, and biomarker analysis of neoadjuvant camrelizumab plus apatinib as a chemotherapy-free strategy for early-stage triple-negative breast cancer: a phase II study},
  journal = {Breast Cancer Research and Treatment},
  year = {2026},
  doi = {10.1007/s10549-026-08066-5}
}
Kostenlos starten →